Clinical Trial Update: Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating autologous B7-H3 CAR T cells in relapsed/refractory solid tumors, including neuroblastoma, sarcoma, and osteosarcoma, currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Osteosarcoma
• Sarcoma

Drugs mentioned

• Autologous B7-H3 CAR T cells (CAR T cells targeting B7-H3)

Snippet

Sponsor: Crystal Mackall, MD | Conditions: Neuroblastoma, Sarcoma | Phase 1 | Status: RECRUITING